{"meshTags":["Albumins","Antineoplastic Combined Chemotherapy Protocols","Deoxycytidine","Humans","Paclitaxel","Pancreatic Neoplasms"],"meshMinor":["Albumins","Antineoplastic Combined Chemotherapy Protocols","Deoxycytidine","Humans","Paclitaxel","Pancreatic Neoplasms"],"publicationTypes":["Journal Article"],"abstract":"Pancreatic cancer remains a vexing treatment challenge, with a cure rate that remains just 7%. Two effective regimens--gemcitabine/nab-paclitaxel and FOLFIRINOX--have improved outcomes and are being used earlier in the disease. However, meaningful differences in outcomes may not be realized without novel strategies. Targeting of the immune system is an active area of research.","title":"Multidisciplinary management of pancreatic cancer.","pubmedId":"25995435"}